EAE was induced by immunization female mice with MOG35–55 peptide emulsified in CFA (Difco Laboratories) at a dose of 100µg (C57BL/6 and F1 mice) or 150µg (NOD mice) per mouse, followed by the administration of pertussis toxin (150 ng per mouse; List biological laboratories, Inc.) on days 0 and 2 as described14 (link). Clinical signs of EAE were assessed according to the following score: 0, no signs of disease; 1, loss of tone in the tail; 2, hind limb paresis; 3, hind limb paralysis; 4, tetraplegia; 5, moribund.GCV (APP Pharmaceuticals), or vehicle control (PBS) was administered daily (25mg/kg, subcutaneously) 7 days before EAE induction and continued for the duration of the acute phase (day 15), or only during the progressive/chronic phase (day 30–50). LacCer (Matreya LLC) or vehicle (10% DMSO), were administered at a dose of 10µg per mouse together with the MOG35–55 peptide to C57BL/6J mice during EAE induction, and also intraperitoneally (i.p.) every other 3 days henceforth. LacCer or vehicle administration to NOD mice were initiated 35 days after disease induction at a dose of 10µg per mouse given i.p. every 3 other days. PDMP (Matreya LLC) or vehicle control (5% tween-80), were administered at day 40 after EAE induction twice a day with 20mg/kg given i.p. for the duration of the experiment.
Protocol detail
Experimental Autoimmune Encephalomyelitis Induction and Treatment
Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link:
Access Free Full Text.
Biological
C57bl mice
Dmso
Female
Hind limb
Hind limb paresis
Immunization
Mouse
Nod mice
Pdmp
Peptide
Pertussis toxin
Pharmaceuticals
Tail
Tetraplegia
Tween 80
Corresponding Organization :
Other organizations : Brigham and Women's Hospital, Harvard University, Montreal Neurological Institute and Hospital, McGill University, Université de Montréal
Top 5 similar protocols
Protocol cited in 5 other protocols
Variable analysis
independent variables
- Immunization with MOG35–55 peptide emulsified in CFA (Difco Laboratories) at a dose of 100 μg (C57BL/6 and F1 mice) or 150 μg (NOD mice) per mouse
- Administration of pertussis toxin (150 ng per mouse; List biological laboratories, Inc.) on days 0 and 2
- Administration of GCV (APP Pharmaceuticals) or vehicle control (PBS) daily (25 mg/kg, subcutaneously) 7 days before EAE induction and continued for the duration of the acute phase (day 15), or only during the progressive/chronic phase (day 30–50)
- Administration of LacCer (Matreya LLC) or vehicle (10% DMSO) at a dose of 10 μg per mouse together with the MOG35–55 peptide to C57BL/6J mice during EAE induction, and also intraperitoneally (i.p.) every other 3 days henceforth
- Administration of LacCer or vehicle to NOD mice initiated 35 days after disease induction at a dose of 10 μg per mouse given i.p. every 3 other days
- Administration of PDMP (Matreya LLC) or vehicle control (5% tween-80) at day 40 after EAE induction twice a day with 20 mg/kg given i.p. for the duration of the experiment
- Clinical signs of EAE assessed according to the following score: 0, no signs of disease; 1, loss of tone in the tail; 2, hind limb paresis; 3, hind limb paralysis; 4, tetraplegia; 5, moribund
- Mouse strains: C57BL/6, F1, and NOD mice
- Dose of MOG35–55 peptide: 100 μg for C57BL/6 and F1 mice, 150 μg for NOD mice
- Route of administration for GCV, LacCer, and PDMP
- None mentioned
- Vehicle control (PBS) for GCV administration
- Vehicle control (10% DMSO) for LacCer administration
- Vehicle control (5% tween-80) for PDMP administration
Annotations
Based on most similar protocols
Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.
Sign up for free or login to display all annotations
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!